The effect of sildenafil citrate and kraussianone-2 on pre-eclampsia-like manifestations in Sprague-Dawley rats. by Ramesar, Shamal Vinesh.
i 
 
THE EFFECT OF SILDENAFIL CITRATE AND KRAUSSIANONE-2 ON                             

















Submitted in partial fulfilment of the requirements for the degree Doctor of Philosophy 
(Physiology) in the School of Basic and Applied Medical Sciences, Faculty of Health 








This study represents the original work of the candidate and has not been submitted in any 
























Pre-eclampsia, often described as toxaemia of pregnancy, historically represents one of the 
most widely investigated conditions relating to human reproduction.  To date no firm cure 
has been found and a clear, well defined mechanism has not been ascribed to the 
pathogenesis of the disease. Researchers seem to focus on single pathways in isolation of 
others.  The disease rather represents a multitude of possible underlying pathologies 
involving genetics, immune dysregulation, vascular maladaptation, and sociobiological 
factors thus complicating the approach to treatment. However, a central theme is the presence 
of reduced placental perfusion resulting in a hypoxic and/or ischaemic placenta and the 
subsequent secretion of various factors that initiate the maternal syndrome. It is within this 
context that we examine how an intervention such as increasing placental perfusion may 
represent a promising treatment strategy for this disease. We sought to manipulate the 
vasodilatory mechanisms of the uterine vasculature using sildenafil citrate and a flavonoid 
extracted from Eriosema kraussianum (Kr2), in Sprague-Dawley rats that exhibited pre-
eclampsia-like manifestations.  Both treatment regimens improved fetal outcomes and 
reduced blood pressure amplification and proteinuria.  They also reduced the plasma 
concentrations of the two anti-angiogenic factors; sFlt1 and sEng.  Only sildenafil citrate 
improved nitric oxide levels which was expected, suggesting that Kr2 causes vasodilation by 
some other mechanism.  Nevertheless, both compounds improved both pup and placental 
weights, suggesting that they also improve utero-placental perfusion. These findings that 
selective uterine vascular dilation improves placental perfusion may be promising in averting 
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CHAPTER ONE - BACKGROUND 
1.1. What is Pre-eclampsia?  
Pre-eclampsia is a specific disorder of pregnancy which is characterised by abrupt 
hypertension, elevated proteinuria and oedema after 20 weeks of gestation resulting in 
intrauterine growth retardation (IUGR) (Khalil and Granger, 2002; Roberts and Gammill, 
2005; Norris et al., 2005). The disease accounts for the highest number of fetal and maternal 
deaths and has an estimated worldwide incidence of 8,370,000 cases per annum (Sibai, 
2003).  The disease contributes to approximately 814,000 neonatal deaths and 1.02 million 
stillbirths annually, and is also the leading cause for the admission of pregnant women to 
intensive care units in the developed world (Sibai, 2003; Norris et al., 2005; Roberts and 
Gammill, 2005).  Developing and under-resourced countries show a threefold increase in 
both fetal and maternal mortality (Lopez-Jaramillo et al., 2001).  Locally, 84% of the 622 
deaths linked to hypertensive disorders in pregnancy between 2005 and 2007 were due to the 
pre-eclampsia/ eclampsia syndrome (Moodley, 2011).  The prevalence of hypertension during 
pregnancy in the province was about 12.5% in 2004 (Panday et al., 2004). In sub-Saharan 
Africa, recent health services assessments found that only 15% of hospitals where equipped 
to provide basic neonatal resuscitation (Wall, 2010) and with the increased daily admissions 
of pre-eclamptic patients this represents an added burden to healthcare in developing 
countries. Clearly, a simple and effective intervention is urgently needed. 
 
1.2. Etiology and Pathogenesis of preeclampsia 
Uterine blood flow is significantly elevated during normal pregnancy to facilitate optimum 
oxygen and nutrient delivery to the developing foetus (Kaar et al., 1980; Pijnenborg et al., 
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1991).  Uterine perfusion pressure changes very little during pregnancy, hence uterine 
vascular resistance must decrease through a combination of functional changes such as 
vasodilatation and structural changes such as growth and remodelling (Kaar et al., 1980; 
Pijnenborg et al., 1991; Khalil and Granger, 2001). In preeclampsia these uterine arteries fail 
to undergo vascular remodelling i.e. instead of conforming to a compliance vessel, it acts as a 
resistance vessel. 
Although the etiology and pathophysiolgy of pre-eclampsia is still not clearly understood, 
many accept the two-stage model of the disease (Roberts and Gammill, 2005).  It is thought 
that this failed vascular remodelling maybe the initiating factor (stage 1) of the disease,  
perhaps as a result of inadequate trophoblast invasion and thus inadequate remodelling of the 
uterine spiral arteries during the first trimester of pregnancy (Figure 1) resulting in vascular 
maladaptation of the placental bed (Pijnenborg et al., 1991, Kaufmann, 2003; Roberts and 
Gammill, 2005). This then translates into a marked reduction in placental blood flow and 
eventually manifests as defective placentation and placental hypoxia. The hypoxic placenta is 
thought to initiate the maternal syndrome (stage 2), by the release trophoblastic debris; 
necrotic tissue; and anti-angiogenic factors which virtually affects every major organ system 
by causing endothelial dysfunction and systemic vasospasm (Maynard et al., 2003; 
Karumanchi et al., 2004; Roberts and Gammill, 2005). These events are depicted sequentially 
in figure 2 below. The condition worsens over time suggesting a positive feedback loop 
centred around soluble fms-like tyrosine-1 (sFlt1) and soluble endoglin (sEng) (Karumanchi 
and Bdolha, 2003; Venkatesha et al., 2006). The only known cure is the delivery of the foetus 
and the placenta.    
The link between stage 1 and 2 of the disease is unknown however a plausible unifying 
hypothesis may be that reduced placental perfusion results in abnormal placentation and 
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hypoxia that ultimately triggers the release of several factors into maternal circulation which 
initiate endothelial dysfunction and the subsequent multi-system organ defects.  
 
 
              Figure 1. Uterine spiral artery remodelling as a result of cytotrophoblast invasion 
                               (http://www.sgul.ac.uk/depts/immunology/troph/spiral.jpg) 
 
  
                         Figure 2: The onion model for the etiology of pre-eclampsia. 
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1.3. Sildenafil citrate (ViagraTM ) 
Sildenafil citrate, popularly marketed under the trade name ViagraTM , has become the 
primary  treatment for erectile dysfunction (ED) since it’s availability in 1998. In addition to 
improving erectile function, this compound has also been shown to be successful in the 
treatment of pulmonary arterial hypertension (Barnett and Machado, 2006) and marketed 
under the trade name RevatioTM for this purpose.  As with many other novel therapeutic 
interventions, sildenafil citrate was discovered by accident in its role of treating ED (Kling, 
1998; Sneader, 2005).  Campbell and Roberts, two UK based scientist, embarked on a search 
for a compound that could lower blood pressure by increasing atrial natriuretic peptide (ANP) 
secretions in 1989 (Sneader, 2005).  They began investigating a compound called Zaprinast, 
introduced to the scientific world by Nicholas Terrett in 1986, but showed little promise for 
this purpose (Kling, 1998).  By adding a sulphonamide to the benzene ring of Zaprinast they 
produced sildenafil which was a 100 times more potent vasodilator and highly specific.  
These properties lead them to the use of sildenafil for the treatment of angina as it was 
thought that sildenafil will be effective in coronary artery vasodilation (Kling, 1998).  Human 
trial for this purpose once again proved disappointing, however male patients were reluctant 
to return their medication after the trial (Morales et al., 1998). It was here that the 
extraordinary effect of sildenafil citrate on male erectile function was discovered. 
The mechanism of action for sildenafil citrate is based on the role of nitric oxide (NO) in 
vascular smooth muscle relaxation (Boolel et al., 1998).  Nitric oxide is produced by the 
deamination of L-arginine into citrulline and NO in the presence of the enzyme nitric oxide 
synthase (NOS) (Moncada and Higgs, 1993).  There are 3 isoforms of this enzyme, i.e. 
endothelial NOS (eNOS), neuronal NOS (nNOS) and inducible NOS (iNOS).  In the case of 
the penile artery, corpora cavernosa and the uterine vasculature, eNOS is the dominant 
isoform (Boolel et al., 1998; Rybalkinin et al., 2001).  Nitric oxide produces its vasodilatory 
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effects through the action of its second messenger, cyclic guanidine monophosphate (cGMP), 
which is produce as a result of NO interaction with iron in the enzyme guanylyl cyclase to 
ultimately phosphorylate guanidine triphosphate (GTP) (Moncada and Higgs, 1993).  In the 
case of reducing male erectile function a specific type-5 phosphodiesterase hydrolyses cGMP 
thereby decreasing the  its vasodilatory effects. Sildenafil citrate (ViagraTM) is a specific type-
5 phosphodiesterase (PDE) inhibitor. It acts as a competitive binding agent for this type-5 
phosphodiesterase and therefore favours cGMP to cause vasodilation of the penile artery and 
relaxation of the copora cavernosa to ultimately cause an erection (Boolel et al., 1998).   
With the discovery of the same family of specific type-5 phosphodiesterase iso-enzymes in 
the uterus and uterine vasculature (Rybalkinin et al., 2001), sildenafil citrate certainly 
warranted investigations into its vasodilatory effect in the female reproductive system. It was 
shown to enhance vasodilation and improve the endothelial function of myometrial vessels in 
pregnancies complicated by intra-uterine growth retardation (IUGR) (Werieng et al., 2005). 
Other researchers have also shown silfendenil citrate (SC) to improve uterine artery blood 
flow and endometrial development in women undergoing in vitro fertilization (Sher and 
Fisch, 2000) as well as having beneficial effects on fetal and vascular parameters in 
hypertensive pregnant rats (Osol et al., 2005). It is within this context that we decided to 
investigate the role of sildenafil citrate on pre-eclampsia. 
 
1.4. Eriosema kraussianum N. E. Br. (Fabaceae) 
Traditional herbal remedies still form an integral part of African culture hence we also chose 
to investigate a viable plant extractive that is commonly used by South African traditional 
healers for ED (Hutchings et al., 1996). The plant in question falls under the genus Eriosema 
(isiZulu indigenous umbrella name of “uBangalala”). The roots of Eriosema kraussianum are 
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used by Zulu traditional healers to treat for erectile dysfunction as follows; hot milk infusions 
of the plant’s roots, or pounded, boiled root decoctions are taken in small doses twice a day 
for impotence (Hulme, 1954; Bryant, 1966; Hutchings et al., 1996). Two bioactive pyrano-
isoflavones [Kraussianone-1 (Kr1) and Kraussianone-2 (Kr2)] were isolated from the roots of 
Eriosema kraussianum N. E. Br. (Fabaceae) (Drewes et al., 2002, 2003). Both bioactive 
compounds demonstrated beneficial effects in the management of erectile dysfunction 
(Drewes et al., 2002, 2003) and further exhibited hypoglycaemic effects and vasodilatory 
properties in a rat model (Ojewole et al., 2006).  Based on our findings of improved fetal 
outcomes using sildenafil citrate and given that ViagraTM is a prescription drug and its 
availability is scarce in under resourced and developing countries we chose to investigate the 
role of one of the flavonoids from Eriosema kraussianum N. E. Br. (Fabaceae) on 
preeclampsia. 
 
1.5. Problem Identification 
In the absence of definitive markers for early detection of pre-eclampsia, the disease 
represents a dilemma for both mother and the developing fetus.  The increased secretion of 
factors from the hypoxic placenta exacerbates the maternal syndrome in a positive feedback 
loop which can only be terminated with expulsion of the placenta and fetus.  All of this 
centers around untransformed spiral arteries, which hypoperfuse the placenta.  It is postulated 
that the non-invasion by the cytotrophoblast during the first trimester of pregnancy leads to 
the production of uterine vascular resistance hence starving the developing fetus of oxygen 
and nutrients.  Whatever the etiopathology, the use of a vasodilator to improve perfusion to 




1.6. Aim:  To improve fetal outcomes and decrease blood pressure and proteinuria with 
sildenafil citrate and kraussianone-2 in Sprague-Dawley rats that exhibit pre-eclampsia-like 
manifestations. 
1.7. Objectives:    
1. To induce an accurate gestational day 0 and pre-eclampsia-like symptoms in Sprague-
Dawley rats. 
2. To determine whether sildenafil citrate and kraussianone-2 improves fetal outcomes 
and reduce blood pressure and urinary protein excretion in Sprague-Dawley rats with 
pre-eclampsia-like manifestations. 
3. To determine the effect of sildenafil citrate and kraussianone-2 on plasma levels of 
pro-angiogenic and anti-angiogenic factors 
4. To determine the mechanism by which sildenafil citrate and kraussianone-2 acts to 















Whenever timed pregnancies are needed, especially during clinical drug trials, deducing an 
accurate Day 0 in rats has been the burden of many scientists. Among the various methods 
for rodent mating, the most common is by simply placing an adult female rat into a cage with 
one or more adult male rats for a 6 day period which will result in the detection of sperm in 
the vaginal tract and pregnancy (Baker, 1980). However the 6 day window period may often 
result in an inaccurate day 0 which may be crucial in clinical trials since rats only have a 21-
23 day gestation period. After many failed attempts using conventional mating techniques, 
we now propose a refined method with exceptional success rates. 
 
2.2. Background 
The Classic work of Long and Evans (1922) described the estrous cycle of the female rat and 
its clinical characteristics as being approximately 4 days in length and consists of 4 stages: 
proestrus, estrus, metestrus and diestrus. The cycle is associated with regular changes in the 
cell types found within the vaginal fluids hence cervical smears can be taken daily to estimate 
each phase of the cycle. Long and Evans (1922) characterized each stage as follows: 
proestrus is characterized by a large number of intermediary cells, parabasal cells are rare and 
leucocytes are completely absent. During the early stages of estrus the smear consists largely 
of keratinized cells that lie singly but aggregate as the phase progresses and by the end of this 
stage form large flakes. Metestrus is characterized by a large number of leucocytes and a few 
intermediary cells. During diestrus the smear consists mainly of traces of secretory material 
with cellular debris, intact cells are very difficult to distinguish however a few parabasal cells 
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and leucocytes may be observed. Maximal sexual receptivity of the female accompanies 
estrus, which in the rat occurs 24 hours into the cycle and is indicated by a dry vagina and 
swollen vulva (Long and Evans, 1922).  
 
2.2.1. The Lee-Boot Effect 
This phenomenon was described by Van der Lee and Boot (1955) and is associated with the 
suppression or prolongation of a rodent’s estrus cycle when females are housed in groups and 
isolated from mature males. An estrogen-dependent pheromone, released via the urine that 
acts on the vomeronasal organ of recipients (Van der Lee and Boot, 1955). This pheromone 
lowers the concentration of luteinizing hormone and elevates prolactin levels thus 
synchronizing or stopping the recipient’s cycle (Van der Lee and Boot, 1955).  
 
Figure 3. Hormonal fluctuations of a rat’s estrus cycle (Staley and Scharfman, 2005). 
Estrogen-dependant pheromones (EDP) lower the concentration of LH during proestrus and 





2.2.2. The Whitten Effect 
The Whitten effect is a phenomenon shown to synchronize the estrus cycle among 
unisexually grouped females and cause vaginal opening when they are exposed to male rat 
pheromone-laden urine (Whitten, 1956; 1957). The production of these pheromones is 
androgen-dependent and is responsible for various endocrine responses in female rodents 
(Whitten, 1956; 1966;  Gangrade and Dominic, 1984).  One such response is that it alters the 
secretory patterns of luteinizing hormone and prolactin and consequently the steroids whose 
secretion is regulated by these two tropic hormones (Whitten, 1966). Since ovulatory function 
is among the most important reproductive consequences of these hormonal processes 
(Whitten, 1966; Gangrade and Dominic, 1984), the Whitten effect is highly successful in 
optimizing female rodent pregnancy.  
 
2.2.3. Objectives 
To optimize the sexual receptivity of female Sprague Dawley rats and hence increases the 
chance of positive mating. 
 
2.3.1. Mating Sprague-Dawley Rats 
Briefly, 32 virgin Sprague-Dawley dams were weaned from sister litters at 5 weeks of age. 
The dams were isolated from their original colony and kept under standard laboratory 
conditions, with access to food and water ad libitum.  At 8 weeks of age, the dams were 
weight-matched and housed in groups of eight in large polycarbonate cages to induce the 
Lee-Boot effect. Bedding was changed bi-weekly to ensure maximal exposure to pheromone 
laden urine. At 10 weeks of age vaginal smears were taken daily (described below) and 
histological analysis was conducted on each sample to determine the phase of estrus.  On 
proestrus, each dam was subjected to the Whitten effect using modified polycarbonate cages 
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(figure 4). On estrus the females were introduced to the larger males to allow for overnight 
mating.  The morning after mating occurred, each female was examined for the presence of a 
vaginal plug or a vaginal swab was taken to detect any sperm under light microscopy.  The 





Figure 4. A modified polycarbonate cage, used to induce the Whitten effect.   
 
2.3.2. Vaginal smears 
 
The blunt tip of a disposable pipette containing 1.0 ml of saline, was lubricated with 
petroleum jelly (Vaseline TM) and gently inserted into the vagina of the female to be 
examined. The saline was expelled into the cervix and the dam was allowed to relax for 2 
minutes.  The pipette was then reinserted and approximately 250 ul of vaginal fluid was 
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withdrawn. This sample was smeared onto a microscope slide and the liquid was evaporated 
using a Bunsen burner. Excess liquid was then removed by dipping the slide into 100% 
alcohol and air-dried.  The slide was then stained by dipping into a 5% solution of Giemsa 
stain (Sigma Chemicals, South Africa) and cleared by dipping in distilled water and allowed 
to air-dry. The slide was then examined under a light microscope .  
  
2.4.1. The Lee-Boot Effect 
Induction of the Lee-Boot effect was highly successful in the synchronization of the dam’s 
estrus cycle.  Each of the 8 animals from each group shared the same phase of the cycle when 
vaginal smears were taken. Figures 5 – 8 were used as a reference. 
 
 
Figure 5. Diestrus. Smear consists of traces of secretory material                       
with cellular debris; and occasional  intact  and  parabasal cells 





 Figure 6. Proestrus. Cells are predominately intermediary and rarely               
                   parabasal cells, mucus and white blood cells.     
                   (http://oslovet.veths.no/teaching/rat/oestrus).   
 
 
Figure 7. Estrus. Smear consists nearly entirely of keratinised  







Figure 8. Metestrus. The smear is dominated by white blood cells and  
intermediary cells. (http://oslovet.veths.no/teaching/rat/oestrus) 
 
 
2.4.2. Pregnancy outcomes 
Late in pregnancy (Day 20) a caesarean section was performed on each animal. Thirty-one of 
the 32 animals initially mated fell pregnant demonstrating a 96.88 % success  rate.                              
 




2.5. Discussion and Conclusion 
 
Although rats are spontaneous ovulators, they do not necessarily become pregnant when 
exposed to mature males. This poses many frustrations in any research protocol especially 
when a timed pregnancy and an accurate day 0 are needed. Various attempts using 
conventional techniques at our animal research unit proved unsuccessful leading to a waste of 
time and resources. The Lee-Boot effect applied in concert with the Whitten effect 
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A B S T R A C T
Objectives: This study aimed to investigate the effects of sildenafil citrate on various fetal and
physiological parameters, including fetal mortality, number of pups, placental weights and micro-
albuminuria in pregnant, L-NAME treated Sprague–Dawley rats.
Study design: Twenty-four pregnant female Sprague–Dawley rats were divided into 3 groups (n = 8). In
the L-NAME treated group (PRE), L-NAME (0.3 g/l, drinking water) was used to induce pre-eclampsia-like
symptoms on day 1 of the experiment. The experimental group (SCT) also received L-NAME (0.3 g/l,
drinking water) on day 1 of the experiment. However, sildenafil citrate (10 mg/kg, s.c., daily) was
administered as the test compound from day 7 until day 19. The experimental control (CON) did not
receive either L-NAME or sildenafil citrate. L-NAME administration was discontinued in both the PRE and
the SCT groups on day 19 of the experiment and the animals were given access to normal drinking water
ad libitum. All the animals were sacrificed on day 20, at which time a laparotomy was performed and the
various fetal parameters measured. On day 0 and day 20, blood pressure measurements were recorded
non-invasively and protein estimations in 24 h urine samples were conducted.
Results: Sildenafil citrate decreased fetal mortality and protein excretion and further demonstrated a
trend toward increasing birth and placental weights in pregnant, L-NAME treated, Sprague–Dawley rats.
In addition, sildenafil citrate administration ameliorated the amplification of the L-NAME induced
hypertension in the SCT group.
Conclusion: We speculate that sildenafil citrate by potentiating the effects of nitric oxide in vivo
improves uterine artery blood flow resulting in improved fetal outcomes in pregnant, L-NAME treated,
Sprague–Dawley rats.
 2009 Elsevier Ireland Ltd. All rights reserved.
Contents lists available at ScienceDirect
European Journal of Obstetrics & Gynecology and
Reproductive Biology
journa l homepage: www.e lsev ier .com/ locate /e jogrb1. Introduction
Pre-eclampsia/eclampsia syndrome is defined as a multi-
system disorder, characterized by the abrupt onset of hypertension
and proteinuria after 20 weeks of gestation in a previously
normotensive, non-proteinuric woman [1]. It is a major cause of
both maternal and fetal morbidity and mortality [1,3]. The
incidence is reported to be between 2 and 7% in well resourced
countries and is up to three times greater in under resourced
countries [2,3].
Recent insights in the understanding of the pathophysiology of
pre-eclampsia indicate that it is regarded as a two-stage disorder
[4]. The first stage is one of vascular maladaptation in the placental* Corresponding author at: Department of Physiology and Physiological
Chemistry, University of KwaZulu-Natal, Private bag X5400, Durban, 4000, South
Africa. Fax: +27 31 260 7132.
E-mail addresses: ramesars@ukzn.ac.za, tombe@ukzn.ac.za (S.V. Ramesar).
0301-2115/$ – see front matter  2009 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.ejogrb.2009.11.005bed due to failure of the uterine spiral arteries to undergo complete
remodelling into wide bore channels, an important vascular
modification in normal pregnancies [4–8]. It has been suggested
that this vascular maladaptation is associated with a marked
reduction in blood flow to the placenta. The second stage is one in
which the reduced blood perfusion induces a hypoxic state
resulting in the release of a variety of substances including
trophoblastic debris, necrotic tissue and excess secretion of anti-
angiogenic factors viz. soluble fms-like tyrosine kinase 1 (sFlt-1);
soluble endoglin (sEng) and reduced secretion of angiogenic
factors; vascular endothelial growth factor (VEGF) and placental
growth factor (PlGF), which affect virtually every major organ
system by causing endothelial dysfunction and systemic vaso-
spasm [9]. If left undiagnosed or untreated, pre-eclampsia results
in major complications to the mother and baby [10]. The only
known cure at present is delivery of the baby and placenta [1,10].
Nitric oxide (NO) is a potent vasodilator that is synthesized
from the amino acid L-arginine (L-Arg), by a family of isoenzymes
called nitric oxide synthase (NOS) [11]. It has been suggested that
S.V. Ramesar et al. / European Journal of Obstetrics & Gynecology and Reproductive Biology 149 (2010) 22–26 23diminished NO activity may be involved in the pathophysiology of
pre-eclampsia. Studies on the levels of endothelial NOS (eNOS)
have been reported to be normal in placental villous tissue of pre-
eclamptic women [12]. However, levels of the NO intracellular
second messenger, cGMP, are shown to be decreased in the
placental circulation of pre-eclamptic women. Therefore, it is likely
that there is a reduced activity or half-life of NO [12]. A probable
mechanism for this reduced NO activity is that NO is rapidly
degraded to perooxynitrite (OONO) by interacting with reactive
oxygen species (ROS), especially the superoxide anion (O2
) which
has been shown to be present in abundance in the pre-eclamptic
placenta [13]. Interestingly, NOS has been shown to not only
synthesize NO but also facilitate O2
 production [14]. Both of these
biochemical mechanisms are tightly regulated by L-Arg, where
sufficient levels of L-Arg have been shown to generate NO only and
depletion of L-Arg causes NOS to produce NO and O2
 [15,16].
These findings have later been confirmed by Noris et al., who
demonstrated that L-Arg levels are lower in pre-eclamptic villous
tissue in comparison to normal tissue [17]. Subsequently the
chronic administration of nitro-L-Arg-methyl ester (L-NAME), a
NOS inhibitor, has been shown to induce a pre-eclampsia-like
syndrome in pregnant rats, i.e. sustained hypertension, proteinuria
and intrauterine growth restriction (IUGR) [7,18].
Since NO may be involved in the pathophysiology of pre-
eclampsia, we sought to investigate a possible intervention with
an intracellular NO system. Sildenafil citrate (ViagraTM), a specific
type-5 phosphodiesterase (PDE) inhibitor has been shown to
potentiate the effects of NO in vivo [19]. Furthermore, it enhances
vasodilation and improves the endothelial function of myometrial
vessels in pregnancies complicated by IUGR [20]. Other research-
ers have also shown sildenafil citrate (SC) to improve uterine
artery blood flow and endometrial development in women
undergoing in vitro fertilization [21] as well as having beneficial
effects on fetal and vascular parameters in hypertensive pregnant
rats [22].
The role of SC, however, in improving pregnancy outcomes in
pre-eclampsia still needs further investigation. In this study, we
examined the effect of SC on fetal outcomes in a hypertensive rat
model by measuring the number of live pups, placental weights
and protein concentration in the urine.
2. Methods
2.1. Animal studies
Ethical permission was obtained from the University of
KwaZulu-Natal Animal Ethics Committee. The animals were
weaned at 4 weeks of age from sister Sprague–Dawley rat litters
and the females were then separated from the males. At 8 weeks of
age, 24 weight-matched female rats (180–200 g) were randomly
divided into 3 groups as follows: Group 1, control [CON] (n = 8);
Group 2, L-NAME only treated group [PRE] (n = 8) and Group 3, SC
and L-NAME treated group [SCT] (n = 8).
The animals were maintained under standard laboratory
conditions for a further 2 weeks on a 12-h light/dark regime
and given access to food and water ad libitum. Thus, prior to
mating, the estrus cycles of these animals were synchronised and
vaginal smears were used to determine the phase of their
respective cycles. On their next proestrus phase, animals were
subjected to the Whitten effect to maximize the sexual receptivity
of the female and increase their chances of positive mating. Hence,
females in estrus now approximately 10 weeks of age, were mated
overnight. The morning after mating had occurred, each animal
was examined for the presence of a vaginal plug or the presence of
sperm in a vaginal smear. The presence of a vaginal plug or sperm
positivity was taken as day 0 of the 21–23 day gestation period.2.2. Treatment regimen
From day 1 of the experiment, the pregnant females were
paired and housed in polypropylene cages where CON group was
given normal drinking water and PRE and SCT groups were given L-
NAME (0.3 g/l) [Sigma–Aldrich, USA] in their drinking water to
induce the pre-eclampsia-like syndrome. From day 7 of the
experiment, each animal was treated via subcutaneous injections,
daily, at 09:00 as follows: the CON and PRE groups were given the
vehicle only (di-methyl-sulfoxide, 0.3 ml) and the SCT group was
treated with the study drug (sildenafil citrate) [Pfizer, UK-92480-
10] dissolved in di-methyl-sulfoxide (10 mg/kg, b.w.) until day 19
of the experiment.
L-NAME administration was discontinued in both the PRE and
SCT groups on day 19 of the experiment and the animals were
given free access to normal drinking water thereafter.
2.3. Blood pressure measurements and urinalysis
The blood pressure of each animal was taken on day 0 and day
20 using the non-invasive tail-cuff method (IITC, Life Science, USA).
Each animal was pre-trained for 3 consecutive days prior to the day
0 blood pressure measurement to minimize stress reactions. On
day 0 and day 19, each animal was housed in an individual
metabolic cage (Techniplast, South Africa) with access to water
only ad libitum. This allowed for a 24-h urine sample collection.
Micro-albumin (MA) levels were detected by PEG enhanced
immuno-turbidometry on the Advia 1800 system (Siemens, USA).
2.4. Sample collection
On day 20, each animal was sacrificed as described below. Each
animal was anaesthetized with halothane (FluothaneTM). Blood
samples were obtained by cardiac puncture and separated into
serum, plasma and whole blood specimens. Thereafter a laparoto-
my was performed to expose the uterine horns. The number of
developed fetuses and their respective placenta were counted,
removed and weighed. The utero-placental tissue, heart, kidney,
liver and brain were rapidly removed, sectioned and either snap
frozen in liquid nitrogen or suspended in formalin or glutaralde-
hyde for further investigations (these data will be reported
separately).
2.5. Statistical analysis
All data were subjected to one-way ANOVA and/or the Tukey–
Kramer Multiple Comparison Test using the GraphPad Instat (v.05)
statistical software package. Results are presented as mean
 standard error of the mean (SEM). A probability value of <0.05,
was considered statistically significant.
3. Results
3.1. Blood pressure measurements
The systolic blood pressures (SBP) of each group were compared
(Fig. 1). There were no significant differences (p > 0.05) in the SBPs
between the groups on day 0 of the experiment, but on day 20
significant differences were noted amongst all three groups, i.e. CON
(135.54  1.17 mmHg) vs. PRE (162.83  0.83 mmHg) [p < 0.001];
CON (135.54  1.17 mmHg) vs. SCT (145.46  1.03 mmHg) [p < 0.001]
and PRE (162.83 0.83 mmHg) vs. SCT (145.46  1.03 mmHg)
[p < 0.001]. There was also a significant change in SBPs (p < 0.001)
from day 0 to day 20 within each group. The percentage change in SBPs
from day 0 to day 20 for all 3 groups was calculated as follows: [(SBP on
day 20–SBP on day 0)/SBP on day 0]  100. The CON group showed a
Fig. 1. The systolic blood pressure of CON, PRE and SCT on days 0 and 20. Blood
pressure was recorded non-invasively using the tail-cuff method. The data is
expressed in millimeters of mercury (mmHg) and presented as mean  SEM. All bars
with different alphabets above are significantly different (p < 0.001) i.e. day 20 vs. day
0 within each group and CON vs. PRE vs. SCT on day 20.
Fig. 3. The fetal weights of CON, PRE and SCT. Fetal weights were measured on day
20 of the experiment using a standard electronic balance, following the laparotomy
and subsequent delivery. The data are expressed in grams (g) and presented as
mean  SEM.
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20.52% increase in SBP.
3.2. Fetal mortality
The number of developed pups was compared amongst the
three groups (Fig. 2). PRE (6.5  0.65) had significantly fewer
developed pups compared to CON (10.25  0.70) (p < 0.01), similarly
SCT (9.75  0.67) had significantly more developed pups compared to
PRE group. There were no statistical differences (p > 0.05) between
the number of developed pups for CON (10.25  0.70) and SCT
(9.75  0.67).
3.3. Pup weights
The average pup weights were compared amongst the three
groups (Fig. 3). The average pup weight of the PRE group
(2.29  0.51 g) was less than that of the CON (2.72  0.43 g) and
SCT (2.59  0.37 g) groups, respectively, but this did not reach
statistical significance (p > 0.05).Fig. 2. The number of live pups for CON, PRE and SCT. The data are expressed as the
average number of live pups for each group and presented as mean  SEM, where (*)
is p < 0.05, for PRE vs. CON and SCT.3.4. Placental weights
The average placental weights amongst the three groups were
compared (Fig. 4). These findings were similar to that of the fetal
weights, where the average placental weight of the PRE group
(0.43  0.03 g) was less than that of the CON (0.47  0.03 g) and SCT
(0.44  0.01 g) groups, respectively, but this did not reach statistical
significance (p > 0.05)
3.5. Micro-albumin
Urinary micro-albumin (MA) levels from 24-h urine samples
were compared (Fig. 5). The CON group showed an increase in MA
levels from day 0 (6.50  1.61 mg/l) to day 20 (7.50  1.04 mg/l), but
this increase did not reach statistical significance (p > 0.05). The PRE
group showed an increase in MA levels from day 0 (8.25  1.60 mg/l)
to day 20 (14.33  5.24 mg/l) but this increase also did not reach
statistical significance (p > 0.05). The SCT group showed a decrease in
MA levels from day 0 (7.17  1.14 mg/l) to day 20 (3.83  0.31 mg/l)
but this decrease was not statistically significant (p > 0.05). Overall
there was no statistical significance among all three groups on day 0
of the experiment, but there was a significant difference between PRE
vs. SCT on day 20 (p < 0.01). The percentage change in urinary MA
concentration from day 0 to day 20 for all three groups was calculatedFig. 4. The placental weights of CON, PRE and SCT. Placental weights were measured
on day 20 of the experiment using a standard electronic balance following delivery
of the pups and subsequent separation from the umbilical cord. The data are
expressed in grams (g) and presented as mean  SEM.
Fig. 5. The micro-albumin concentration in 24 h urine samples of CON, PRE and SCT
on day 0 and day 20. The data are expressed in milligrams of micro-albumin per
24 h urine sample and presented as mean  SEM, where (*) is p < 0.05 for PRE vs. SCT
on day 20.
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CON group showed a 15.38% increase, PRE showed a 73.70% increase
and SCT showed a 46.58% decrease in MA concentration.
4. Discussion
This study showed that the administration of SC (10 mg/kg, s.c.)
in pregnant, L-NAME treated, Sprague–Dawley rats significantly
increased the number of live pups (p < 0.01), with corresponding
improvements in both the pup and placental weights. Although SC
ameliorated the effects of L-NAME on fetal parameters, it did not
completely eliminate the L–NAME induced hypertension. It did,
however, reduce further amplification of the systolic blood
pressure when compared to the PRE group. These findings were
consistent with that of Osol et al. [22]. However, those authors did
not report on urinary micro-albumin levels, placental and fetal
weights [22]. Our study demonstrated that SC improved the pup
and placental weights when compared to their respective controls.
It is likely the placental perfusion was improved by the
administration of SC, since placental and pup weights are direct
markers of utero-placental blood flow [23].
It has been documented that there is a gradual increase in
proteinuria throughout pregnancy as a result of selective
glomerular filtration and non-selective re-absorption in the
proximal tubule [24]. Thus the increase in micro-albuminuria
seen in the CON group was expected. The rise in urinary micro-
albumin concentration seen in the PRE group was also expected
since L-NAME has been shown to elevate urinary protein excretion
[18]. The decrease in urinary micro-albumin excretion during
gestation seen in the SCT group bears contrast to the findings of
others during normal and pre-eclamptic pregnancies [24,25].
Current investigations being pursued by us into the exact
mechanism by which SC produces its effects will probably shed
more light on this result. It can be speculated that the increased NO
levels in the SC group could have impacted on the functioning of
the glomerular filtration membrane through its effects on the
capillary endothelium.
Sher and Fisch reported that vaginal SC (25 mg) improved
uterine artery blood flow, and sonographic endometrial thicknessin 4 patients undergoing in vitro fertilization with a history of poor
endometrial response to ovulation induction agents [21]. In
addition, Wareing et al. found that SC significantly reduces
vasoconstriction in biopsies of myometrial vessels, obtained from
normal pregnant females and those whose pregnancies were
complicated by IUGR [20].
Since SC is a specific type-5 PDE inhibitor, it potentiates the
effects of NO by preventing the degradation of cGMP and hence
augments a vasodilatory effect [19]. We therefore speculate that it
is these vasodilatory effects that resulted in improved placental
perfusion and an increase in rat placental weights and increased
number of pups which survived. Further investigations will need to
be conducted to determine exactly which components of the
vascular system were altered to bring about this improved blood
flow.
Sildenafil citrate may also affect vascular remodelling and thus
improve placentation by acting as a NO donor. Insufficient spiral
artery remodelling due to defective trophoblast invasion is
probably an initiating event in the pathogenesis of pre-eclampsia.
Pijnenborg et al. have linked spiral artery changes to vasodilators
such as NO and CO which are involved in priming/vasodilation
prior to remodelling of the spiral arteries [26]. In the guinea pig,
Nanaev et al. reported that maternal arterial vasodilation precedes
endovascular trophoblast invasion and NO production by the
cytotrophoblasts may mediate spiral artery transformation [27].
Lyall refuted these findings, suggesting that NO is not involved in
the dilation of spiral arteries during placentation [28]. Clearly
further work needs to be done to elucidate the exact function of NO
in vascular remodelling.
In conclusion, the effects on fetal outcomes and micro-
albuminuria in pregnant, L-NAME treated, Sprague–Dawley rats
indicates that SC may have a role in the treatment of pre-
eclampsia. The exact molecular mechanism through which SC
mediates its effects still needs to be determined.
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1. Introduction
Pre-eclampsia is characterized by an abrupt onset of hyperten-
sion and proteinuria after 20 weeks of gestation [1,2]. It affects 3–
5% of first pregnancies and is characterised by widespread
endothelial dysfunction [3]. The etiology of pre-eclampsia is still
not clearly understood, but it is known that the pathogenic process
begins much earlier than the presenting symptoms, perhaps at the
onset of trophoblast invasion and remodelling of the spiral arteries
during the first trimester of pregnancy [2,3]. It is thought to be
associated with vascular maladaptation in the placental bed due to
this failure of the uterine spiral arteries to undergo complete
remodelling into wide bore channels resulting in a marked
reduction in blood flow to the placenta [2,4,5]. The reduced
placental blood perfusion induces a hypoxic state resulting in the
release of a variety of substances including trophoblastic debris
and necrotic tissue coupled with an excess secretion of anti-
angiogenic factors, viz. soluble fms-like tyrosine kinase 1 (sFlt-1)
and soluble endoglin (sEng). Several groups of researchers have
proposed that these excess levels of circulating sFlt-1 may cause
the maternal syndrome [6–9].
sFlt-1 has been shown to block the effects of the free or
physiological active form of vascular endothelial growth factor
(VEGF) by inhibiting interactions with both its receptors (VEGFR-1
and VEGFR-2) [10,11]. Similarly, it also inhibits another member of
the VEGF family of growth factors i.e. placental growth factor
(PlGF), which is produced by the placenta [12]. This subsequently
affects virtually every major organ system by causing endothelial
dysfunction and systemic vasospasm [13]. If undiagnosed or
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A B S T R A C T
Objectives: We have previously shown that sildenafil citrate improves various fetal outcomes in
pregnant, L-NAME treated, Sprague–Dawley rats. We therefore aimed to identify which component/s of
this diverse pathophysiologic cascade is/are improved by this drug.
Study design: This study is a sub-analysis of plasma samples obtained in a previous study in which 24
pregnant Sprague–Dawley dams were divided into three groups (n = 8) i.e. the control group (CON), the
experimental control group (PRE) where the pre-eclampsia-like symptoms were induced using L-NAME,
and the experimental group (SCT) where the pre-eclampsia-like symptoms were once again induced
using L-NAME but these animals were treated with sildenafil citrate. On gestation day 20 blood samples
were collected in heparin-coated tubes and plasma samples were then analysed for specific variables
using commercially available kits for rats.
Results: There was a significant increase in the plasma levels of soluble fms-like tyrosine kinase1 (sFlt-1)
in the PRE group (1228.80  116.29 pg/ml) when compared to the CON (774.91  26.81 pg/ml) and SCT
(698.98  20.78 pg/ml) groups, respectively (p < 0.001). The plasma levels of soluble endoglin (sEng) were
significantly decreased in the SCT group (149.47  3.72 ng/ml) when compared to the CON
(178.52  5.33 ng/ml) and PRE (183.44  8.294 ng/ml) groups, respectively (p < 0.01). Plasma nitric oxide
and L-arginine levels showed a decreasing trend in the PRE groups when compared to the control (CON) and
treated (SCT) groups, respectively.
Conclusion: Sildenafil citrate reduces the plasma levels of anti-angiogenic factors, sFlt-1 and sEng, in pre-
eclamptic (L-NAME induced) Sprague–Dawley rats and may therefore be responsible for the reduction in
blood pressure and proteinuria as well as the improved fetal outcomes noted in an earlier study.
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untreated, pre-eclampsia results in major complications to mother
and baby [14]. The only known cure at present is delivery of the
baby and placenta [1,14].
Endoglin, a cell-surface co-receptor for transforming growth
factor (TGF)-b1 and TGF-b3 isoforms, also plays a key role in
angiogenesis [15–17]. Circulating sEng has been shown to be
elevated in pre-eclamptic compared to normotensive healthy
pregnant women [18]. Administration of sEng on its own does not
produce the symptoms of severe pre-eclampsia but co-adminis-
tration with sFlt-1 showed increased proteinuria, severe hyper-
tension and biochemical evidence of the HELLP syndrome. The
authors concluded that these soluble factors act in concert to block
the proangiogenic effects of VEGF and TGF-b1 and disrupt
endothelial integrity, thereby causing considerable vascular
damage [19].
A number of animal models have been used to study the
pathogenesis of pre-eclampsia [20–26]. We [27] and others
[22,23,28] have successfully shown that inhibition of nitric oxide
synthase with L-NAME can also be used as a good animal model to
reproduce a pre-eclampsia-like syndrome in which there is
hypertension, proteinuria and reduced placental and pup mass.
We further showed that the administration of sildenafil citrate (SC)
in this model led to a significant reduction in pup fatality, coupled
with a decrease in high blood pressure and proteinuria and a
corresponding increase in pup and placental mass [27].
In this study, we intend to show the molecular mechanism by
which L-NAME produces the pre-eclampsia-like syndrome and
how SC can be used to reverse some of the changes.
2. Methods
The animal model was described by us previously [27]. Briefly,
24 pregnant Sprague–Dawley dams were randomly divided into
three groups as follows: control group [CON] (n = 8), experimental
control group [PRE] (n  8) and the SC treated group [SCT] (n = 8).
The pre-eclampsia-like syndrome was induced in PRE and SCT by
adding L-NAME (0.3 g/l) [Sigma–Aldrich, USA] to their drinking
water from gestation day 1 until day 19, and CON was given
normal water only. Administration of sildenafil citrate [Pfizer, UK-
92480-10] (10 mg/kg, b.w.) began on gestation day 7 and
continued daily until day 19. The CON and PRE groups were
given vehicle only (di-methyl-sulfoxide, 0.3 ml). The animals
were maintained under standard laboratory conditions on a 12-h
light/dark regime and given access to food and their respective
drinking water ad libitum. Animals were anaesthetized with
halothane (FluothaneTM) on gestation day 20 and blood samples
were obtained via cardiac puncture in heparin coated tubes. The
plasma samples were separated and stored at 70 8C and later
analysed for this study.
Plasma nitric oxide (NO) levels were measured following the
reduction of nitrate to nitrite by an improved Griess method, using
a commercially available kit according to the manufacturer’s
protocol (BioAssay Systems, USA). L-Arginine levels were measured
in the plasma by using a chromogen that forms a coloured complex
with urea that is produced by arginase activity. This was achieved
by a commercially available kit (BioAssay Systems, USA). Plasma
levels of angiogenic factors (VEGF and PlGF) and anti-angiogenic
factors (sFlt-1 and sEng) were measured by quantitative sandwich
enzyme immunoassay techniques using commercially available
kits for rats according to the manufacturers protocol (R&D Systems,
USA).
All data were subjected to one-way ANOVA and/or the Tukey-
Kramer Multiple Comparison Test using the GraphPad Instat (v.05)
statistical software package. Results are presented as mean
 standard error of the means (SEM). A probability value of <0.05,
was considered statistically significant.
3. Results
Changes in mean plasma levels of sFlt-1 and sEng are shown in
Figs. 1 and 2, respectively. The plasma concentration of sFlt-1 in the
PRE group (1228.80  116.29 pg/ml) was significantly elevated
when compared to the CON (774.91  26.81 pg/ml) and SCT
(698.98  20.78 pg/ml) groups, respectively (p < 0.001). There was
no statistical significance between the CON and SCT groups. The
plasma concentration of sEng in the SCT group (149.47  3.72 ng/ml)
was significantly decreased when compared to the CON
(178.52  5.33 ng/ml) and PRE (183.44  8.294 ng/ml) groups, re-
spectively (p < 0.01). There was no statistical significance between
the CON and PRE groups.
The plasma levels of NO in the PRE group (9.87  0.59 mM) were
decreased compared to the CON (11.20  1.05 mM) and SCT
(11.92  3.70 mM) groups, respectively (Fig. 3). This did not reach
statistical significance (p > 0.05), however. The plasma levels of L-Arg
were decreased in both the PRE (5.08  0.81 mM) and SCT
(6.26  0.24 mM) groups compared to the CON group
(10.47  2.31 mM) (Fig. 3) but this did not reach statistical signifi-
cance (p > 0.05). There was no significant difference in the plasma
concentration of VEGF and PlGF for CON versus PRE and SCT groups,
respectively (Fig. 4).
Fig. 1. Plasma sFlt-1 levels for CON, PRE and SCT, respectively. Plasma sFlt-1 levels
were determined by quantitative sandwich enzyme immunoassay. The data are
expressed in picograms per milliliter (pg/ml) and presented as mean  SEM, where
(***) is p < 0.001 for PRE versus CON and SCT.
Fig. 2. Plasma sEng levels for CON, PRE and SCT, respectively. Plasma sEng levels
were determined by quantitative sandwich enzyme immunoassay. The data are
expressed in nanograms per milliliter (ng/ml) and presented as mean  SEM, where
(**) is p < 0.01 for SCT versus PRE.


















L-NAME is known to induce a pre-eclampsia-like syndrome in
animal models by causing hypertension, increased proteinuria and
intrauterine growth restriction (IUGR) [4]. We have successfully
demonstrated this in a previous study, where the PRE group, which
was treated with L-NAME from gestation day 1 through till day 19,
showed a significant elevation of blood pressure, proteinuria and
IUGR compared to the control animals [27]. Chen et al. also
observed blood pressure and proteinuria to be significantly
increased in a rat model of pre-eclampsia using L-NAME [23].
Of importance, however, was that the co-administration of SC
(10 mg/kg, s.c.) to the SCT group, in which the pre-eclampsia-like
syndrome was also produced with L-NAME, demonstrated a
marked reduction in maternal high blood pressure and proteinuria
and an improvement in fetal outcomes by significantly increasing
the number of developed pups with corresponding improvements
in both the pup and placental masses [27].
In the present study we now show a significant increase in
plasma sFlt-1 concentration in the PRE group compared to the
control group. Gilbert et al., using the reduced uterine pressure
model in pregnant rats, also found significantly raised plasma sFlt-
1 levels compared to normotensive healthy pregnant rats [26]. The
source of circulating sFlt-1 could be placental and non-placental in
origin, such as circulating mononuclear cells [25,29]. Several other
researchers have also shown plasma sFlt-1 levels to be raised in
pre-eclampsia compared to normotensive pregnancies [6,7,30,31].
We further found that the raised sFlt-1 levels were accompanied by
significantly raised sEng levels.
The plasma concentrations of both angiogenic factors (VEGF
and PlGF) in this study, whilst being at very low levels, did not
differ amongst the groups. Since angiogenesis has been shown to
occur during the first trimester of pregnancy [32,33] and our blood
samples were obtained late in the third trimester, the low levels of
angiogenic factors found in all three groups are in keeping with the
findings of Zygmunt et al. The imbalance between the anti-
angiogenic and angiogenic factors could have caused maternal
endothelial dysfunction leading ultimately to a multi-organ
disorder and the resultant hypertension, proteinuria and fetal
and placental changes seen in our previous study [27].
Turgut et al. showed in an elegant experiment that the use of SC
in a rat pre-eclamptic model increases cGMP content in thoracic
aortic muscle rings and straightened the relaxation and contrac-
tion responses but not to control levels [34]. We therefore believe
that SC increases the synthesis and secretion of NO by maternal
blood vessels, thus resulting in improved placental circulation and
reduced hypoxia. We did not, however, find a significant increase
in NO levels in plasma samples in the SCT group compared to the
PRE group, though there was a tendency towards an increase.
Sildenafil citrate, commonly used to treat male erectile
dysfunction, is a specific type-5 phosphodiesterase (PDE) inhibitor.
It potentiates the effects of NO by preventing the degradation of
cGMP and hence augments a vasodilatory effect [35]. We speculate
that it is these vasodilatory effects that results in improved
placental perfusion and therefore reduces the clinical symptoms of
this disease. We believe that the tendency of plasma NO levels to
decrease in the PRE group compared to the CON group may be due
to the degradation of NO to peroxynitrite (OONO) by interacting
with reactive oxygen species (ROS), such as superoxide anion
(O2
), which has been shown to be increased in the pre-eclamptic
placenta [36]. The enzyme nitric oxide synthase (NOS) is well
established in its role of NO synthesis, but it also facilitates O2

production [37]. L-Arg is central in both of these biochemical
mechanisms, where sufficient levels of L-Arg have been shown to
generate NO only, but decreased levels of L-Arg cause the enzyme
NOS to produce NO and O2
 [38–40]. Thus the trend of decreased L-
Arg in the PRE group justifies the trends of decreased NO levels.
Other studies have reported similar findings which showed that L-
Arg levels are lower in pre-eclamptic villous tissue in comparison
to normal tissue [41].
Plasma L-Arg levels also demonstrated a tendency to decrease in
SCT but there was a tendency of plasma NO levels to increase in
this group. This perhaps suggests that the administration of SC
prevents the degradation of NO to OONO. This begs the question
as to whether SC antagonizes O2
 formation. Recent studies have
reported that SC administration in rabbit [42] and mouse [43]
models inhibit O2
 formation and action. These findings explain
the tendency of increase in plasma NO levels seen in SCT when
compared to the PRE group, even though L-Arg levels were
decreased in both groups.
As mentioned previously, exogenous gene transfer of sFlt-1 in
pregnant rats displayed various phenotypes of pre-eclampsia
including hypertension, proteinuria and glomerular endotheliosis
[6] and the co-administration of sEng in the same animal caused
haemolysis and thrombocytopenia which are also notable
phenotypes of the disease. Hara et al. demonstrated that elevated
circulating sFlt-1 may result in proteinuria by downregulating
renal nephrin [44]. Venkatesha et al. concluded that increased
circulating sFlt-1 levels play a role in the development of
hypertension by opposing the physiological effects of NO-
dependent vasodilation.
Placental and fetal weights are strongly correlated with
uteroplacental blood flow [45]. Furthermore, Makris et al. induced
uteroplacental ischemia (UPI) in a pregnant non-human
primate model and found that UPI produced clinical changes
Fig. 3. A comparison of the plasma nitric oxide and L-arginine levels for CON, PRE
and SCT, respectively. Plasma nitric oxide and L-arginine levels were determined by
ELIZA. The data are expressed in micromoles (mM) and presented as mean  SEM.
Fig. 4. Plasma angiogenic factor levels for CON, PRE and SCT, respectively. Plasma
VEGF and PlGF levels were determined by quantitative sandwich enzyme
immunoassay. The data are expressed in picograms per milliliter (pg/ml) and
presented as mean  SEM.








similar to pre-eclamptic women, i.e. hypertension, proteinuria and
renal histological changes [25]. We can therefore deduce that the
increased levels of circulating sFlt-1 in our PRE group correlate
with placental hypoxia [32] thus causing the decrease in placental
mass and IUGR described in our previous study [27]. In addition,
the elevated plasma sFlt-1 and sEng levels in the same PRE group
could also be responsible for the elevated blood pressure [19] and
proteinuria [44].
Of importance in our study is that the administration of SC in
our model resulted in reduced plasma sFlt-1 and sEng levels,
thereby reducing the high blood pressure and proteinuria and
hence causing the corresponding improvement in fetal outcomes
including increased survival and pup and placental masses. As far
as we are aware, this is the first time that such a phenomenon has
been demonstrated in an animal model.
The limitations of this study were the small sample size, the fact
that blood samples were not obtained in early gestation and the
fact that the expression of sFlt-1 and eNOS mRNA levels in the
placenta was not done. We recommend that further investigations
will need to be conducted to determine exactly which components
of the vascular system were altered to bring about this improved
blood flow and whether the circulating sFlt-1 is indeed placental in
origin.
In conclusion, the effects of SC on the various fetal outcomes,
hypertension, micro-albuminuria and anti-angiogenic factors in an
L-NAME-induced pre-eclampsia-like syndrome in our rat model
suggest that it may have a potential role in the treatment of pre-
eclampsia.
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CopyrightThe Effect of Kraussianone-2 (Kr2), a Natural
Pyrano-isoflavone from Eriosema kraussianum, in
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University of Kwa Zulu-Natal, Durban, South AfricaThis study aimed to investigate the effects of Kraussianone-2 (Kr2), a pyrano-isoflavone isolated from the roots of
Eriosema kraussianumN. E. Br. (Fabaceae) on various fetal and physiological parameters in pregnant, L-NAME
treated Sprague–Dawley rats. Twenty-four pregnant Sprague–Dawley dams were divided into three groups
(n= 8), i.e. the control group (CON), the experimental control group (PRE), where the pre-eclampsia-like
symptoms were induced using L-NAME, and the experimental group (EK2), where the pre-eclampsia-like symp-
toms were once again induced using L-NAME, however, these animals were treated with Kr2. On gestation day 20
the animals were sacrificed, at which time a laparotomy was performed and the number of live pups were counted
and their corresponding birth and placental weights were recorded. Blood was also collected in heparin-coated
tubes and the plasma samples were then analysed for specific variables using commercially available kits for rats.
Kraussianone-2 administration decreased fetal mortality and demonstrated a trend toward increasing birth and
placental weights in this model. Furthermore, Kr2 administration also reduced blood pressure amplification and
decreased the plasma concentrations of two antiangiogenic factors, soluble fms-like tyrosine kinase1 (sFlt-1)
and soluble endoglin (sEng). We speculate that Kr2, by improving uterine artery blood flow, results in improved
fetal outcomes and decreased antiangiogenic factors in pregnant, L-NAME treated, Sprague–Dawley rats.
Copyright © 2012 John Wiley & Sons, Ltd.
Keywords: Eriosema kraussianum; Kraussianone-2; pre-eclampsia; soluble fms-like tyrosine kinase1; soluble endoglin.INTRODUCTION
The pre-eclampsia/eclampsia syndrome is defined as a
multisystem disorder, characterized by the abrupt onset of
hypertension and proteinuria after 20weeks of gestation in
a previously normotensive, non-proteinuric woman (Noris
et al., 2005). It is a major cause of both maternal and fetal
morbidity and mortality (Lopez-Jaramillo et al., 2001; Sibai,
2003; Noris et al., 2005). The incidence is reported to be
between 2 and 7% in well-resourced countries and is up
to three times greater in under-resourced countries
(Lopez-Jaramillo et al., 2001; Sibai, 2003).
To date its exact aetiology remains elusive, however,
many have accepted the two-stage model of the disease
(Roberts and Gammill, 2005). The first stage is failed
vascular remodelling leading to reduced placental
perfusion (Pijnenborg et al., 1991; Roberts and Gammill,
2005). This then translates into a hypoxic placenta. The
second stage, the maternal stage, is a multisystemic
syndrome possibly initiated by systemic vasospasm as a
result of endothelial dysfunction (Noris et al., 2005;
Roberts and Gammill, 2005). The link between the two
stages have been the target of many investigations sinceondence to: S. V. Ramesar. Department of Physiology and
cal Chemistry, University of KwaZulu-Natal, Private bag
urban, South Africa, 4000.
mal.ramesar@yahoo.com
© 2012 John Wiley & Sons, Ltd.the early 1970s and has thus been described as the ‘holy
grail’ of pre-eclampsia research (Roberts and Gammill,
2005). Many plausible linkages have been hypothesized,
with the most common being oxidative stress (Roberts
and Hubel, 1999; Redman and Sargent, 2000; Regan
et al., 2001; Raijmakers et al., 2004) and the role of antian-
giogenic factors (Kendall and Thomas, 1993; He et al.,
1999; Maynard et al., 2003, 2005; Venkatesha et al., 2006).
To date no conclusive link between the two stages of
this disease has been identified. Therefore, our group
decided to investigate a possible therapeutic interven-
tion of the disease even after the onset of clinical
symptoms. Since reduced placental perfusion seems to
be central in the pathogenesis of pre-eclampsia our
aim was to increase utero-placental blood flow by select-
ive vasodilation of the uterine vasculature.
Some studies (Sher and Fisch, 2000; Osol et al., 2005;
Wareing et al., 2005), including those conducted in our
laboratories (Ramesar et al., 2009), have examined the
use of sildenafil citrate (Viagra™) as a means of causing
selective uterine vascular dilation. Type–5 PDE isoen-
zymes are largely found in the corpora cavernosa ofmales
and the uterus and uterine vasculature of females
(Buhimschi et al., 2004) and are known to antagonize
the second messenger cGMP. Since sildenafil citrate is a
specific type-5 PDE inhibitor, it augments the vasodila-
tory effect of nitric oxide (NO) by increasing the amount
of free cGMP for vasodilation (Boolell et al., 1996).Received 15 February 2011
Revised 06 July 2011
Accepted 29 September 2011
S. V. RAMESAR ET AL.Viagra™, however, is a prescription drug and its
availability is scarce in under-resourced countries. As
an alternative, and since traditional herbal remedies still
form an integral part of African culture, we chose to
investigate viable plant extractives that mimic the effect
of Viagra™ in vivo. One such plant is the genus
Eriosema (isiZulu indigenous umbrella name of
‘uBangalala’), the roots of which are used by Zulu
traditional healers to treat for erectile dysfunction
(Hulme, 1954; Bryant, 1966; Hutchings et al., 1996).
Hot milk infusions of the plant’s roots, or pounded,
boiled root decoctions are taken in small doses twice a
day for impotence (Hulme, 1954; Bryant, 1966). Two
bioactive pyrano-isoflavones [Kraussianone-1 (Kr1)
and Kraussianone-2 (Kr2)] were isolated from the roots
of Eriosema kraussianum N. E. Br. (Fabaceae) (Drewes
et al., 2002, 2003). Both bioactive compounds demon-
strated beneficial effects in the management of erectile
dysfunction (Drewes et al., 2002, 2003) and further
exhibited hypoglycaemic effects and vasodilatory
properties in a rat model (Ojewole et al., 2006).
As we postulate that increased utero-placental blood
flow will alleviate the symptoms of pre-eclampsia,
we aim to investigate the effects of E. kraussianum
extract (Kr2) in an L-NAME induced pre-eclamptic
rat model.METHODS
Plant material. Eriosema kraussianum N. E. Br.
(Fabaceae) was collected from an open grassland on
the northern boundary of the National Botanical
Garden in Pietermaritzburg, South Africa. Identifica-
tion of the plant was by Professor Trevor Edwards
(Curator of the Bews Herbarium at the University of
KwaZulu-Natal, Pietermaritzburg). A voucher speci-
men of the plant (S.E.D. No. 7) has been deposited in
the Herbarium.
Preparation of kraussianone-2 (Kr2). Kraussianone-2
was prepared as described by Drewes et al. (2002).
Briefly, 700 g of E. kraussianum (rootstock) was milled
and extracted with CH2Cl2 for 3weeks to give a brown
powder (7.1 g). On a thin-layer chromatography (TLC)
plate (using CH2Cl2 as solvent), five fluorescent bands
were clearly seen and the band for Kr2 was easily
identified because it is known to migrate at an Rf value
of 0.20. The extract of Kr2 was then isolated in
crystalline form to give 230mg from 6.2 g of the starting
material. The structure of Kr2 was subsequently verified
by spectroscopic techniques (described by Drewes et al.,
2002).
Animal studies. The animal model was described in
detail by us previously (Ramesar et al., 2009). In brief,
ethical permission was obtained from the University of
KwaZulu-Natal Animal Ethics Committee. Twenty-four
virgin Sprague–Dawley dams approximately 10weeks
of age, were mated overnight. The presence of a vaginal
plug or sperm positivity in vaginal smears, the morning
after mating occurred was taken as Day 0 of the
21–23 day gestation period. The animals were divided
into three groups (n= 8), where group 1 was the control
group (CON), group 2 served as the pre-eclampticCopyright © 2012 John Wiley & Sons, Ltd.group (PRE) and group 3 was the experimental group
(EK2). Pregnant females were then paired and housed
together in polypropylene cages.Treatment regimen. From day 1 of the experiment, CON
was given normal drinking water and PRE and EK2
were given L-NAME (0.3 g/L) (Sigma-Aldrich, USA) in
their drinking water to induce the pre-eclampsia-like
syndrome.Drug administration, as described below, began
on day 7 of the experiment and continued, promptly at
09:00 hours daily, until day 19. Each animal was treated
via subcutaneous injection as follows; the CON and PRE
groups were given the vehicle only (dimethyl sulphoxide;
DMSO), 99.5%, analytical grade) (Sigma-Aldrich, USA)
at a concentration that did not exceed 1 uL/g. The EK2
group was treated with kraussianone 2 (Drewes et al.,
2002) dissolved in DMSO at a final concentration of
10mg/mL and injected (i.m.) at a rate of 10mg/kg (b.w.).
The animals were maintained under standard labora-
tory conditions on a 12-h light–dark cycle and given
access to food and their respective drinking water ad
libitum until day 19 of gestation.Blood pressure measurements. Blood pressure record-
ings were taken on days 0 and 20 of the experiment using
the non-invasive tail-cuff method (IITC, Life Science,
USA). Stress reactions were minimized in the experiment
by pretraining each animal for three consecutive days
prior to day 0.Sample collection.On day 20 each animal was anaesthe-
tized with halothane (Fluothane™). Blood samples
were obtained by cardiac puncture and separated into
plasma specimens using heparin coated tubes. Following
euthanasia with excess administration of halothane, a
subsequent laparotomy was performed to expose the
uterine horns. The number of developed fetuses and
their respective placentas were counted, removed and
weighed.Determination of angiogenic and antiangiogenic factors.
Plasma levels of angiogenic factors (VEGF and PlGF)
and antiangiogenic factors (sFlt1 and sEng) were mea-
sured by quantitative sandwich enzyme immunoassay
techniques using commercially available kits for rats
according to the manufacturer’s protocol (R&D Systems,
USA).Determination of nitric oxide levels. Plasma levels of
nitric oxide was measured by quantitative colorimetric
techniques using commercially available kits according
to the manufacturer’s protocol (Quantichrom™, Bio-
Assay Systems, USA).Statistical analysis. All data was subjected to one-way
ANOVAand/or the Tukey-KramerMultiple Comparison
Test using the GraphPad Instat (v.05) statistical software
package. Results are presented as mean standard error
of the means (SEM). A probability value of< 0.05 was
considered statistically significant.Phytother. Res. (2012)
KRAUSSIANONE-2 IMPROVES FETAL OUTCOMES IN A PRE-ECLAMPTIC RAT MODELRESULTS
Blood pressure measurements
The systolic blood pressures (SBP) of each group were
compared (Fig. 1). There were no significant differences
in the SBPs between the groups on day 0 of the experi-
ment, however, on day 20 there was a significant differ-
ence (p< 0.001) amongst all three groups, i.e. CON
(135.54 1.17mmHg) versus PRE (162.83 0.83
mmHg); CON versus EK2 (146.92 1.54mmHg) and
PRE versus EK2. There was also a significant increase
in SBPs (p< 0.001) from day 0 to day 20 within each
group. The percentage change in SBPs from day 0 to
day 20 was calculated, where CON showed a 13.26%
increase, PRE showed a 36.11% increase and EK2
showed a 20.26% increase in SBP.Fetal mortality
The number of developed pups was compared amongst
the three groups (Fig. 2). Group PRE (6.29 0.71) had
significantly fewer developed pups compared withFigure 1. The systolic blood pressure of CON, PRE and EK2 on days
0 and 20. Blood pressure was recorded non-invasively using the tail-
cuff method. The data are expressed in millimeters of mercury
(mmHg) and presented asmeanSEM. All barswith different letters
above are significantly different (p<0.001), i.e. day 20 versus day 0
within each group and CON versus PRE versus EK2 on day 20. This
figure is available in colour online atwileyonlinelibrary.com/journal/ptr.
Figure 2. The number of live pups in CON, PRE and EK2. The data
are expressed as the average number of live pups for each group
and presented as meanSEM, where (*) is p<0.05 for PRE
versus CON and EK2. This figure is available in colour online at
wileyonlinelibrary.com/journal/ptr.
Copyright © 2012 John Wiley & Sons, Ltd.CON (10.25 0.70) and EK2 (10.05 0.65) (p< 0.01).
There were no statistical differences (p> 0.05) between
the number of developed pups for CON and EK2.Fetal weights
The fetal masses for the three groups are shown in Fig. 3.
The average pup mass of the PRE group (2.29 0.51 g)
was less than that of the CON (2.72 0.43 g) and EK2
(2.71 0.21 g) groups, respectively. However this did
not reach statistical significance (p> 0.05).Placental weights
The average placental masses for the three groups are
shown in Fig. 3. These findings were similar to that of
the fetal masses where the average placental mass of
the PRE group (0.43 0.03 g) was less than that of the
CON (0.47 0.03 g) and EK2 (0.44 0.0 g) groups,
respectively. However, this did not reach statistical
significance (p> 0.05).Angiogenic factors
There was no significant difference in the plasma
concentration of VEGF for CON versus PRE and
EK2 (p> 0.05). Similarly there was no significant
difference in the plasma concentration of PlGF for
CON versus PRE and EK2 (p> 0.05).Antiangiogenic factors
The plasma concentration of sFlt1 in PRE (1228. 80
116.29pg/mL) was significantly elevated when compared
with CON (774.91 26.81pg/mL) and EK2 (777.71 81.96
pg/mL) (p< 0.001; Fig. 4). Furthermore, there was no statis-
tical difference betweenCONandEK2. The plasma concen-
tration of sEng in EK2 (148.67 5.26ng/mL) was
significantly decreased when compared with CON
(178.52 5.33ng/mL)) and PRE (183.44 8.294ng/mL)
groups (p< 0.01; Fig. 5). Interestingly, therewas no statistical
significance between CON and PRE (p> 0.05).Figure 3. The fetal and placental weights of CON, PRE and EK2.
Fetal and placental weights were measured on day 20 of the
experiment using a standard electronic balance. The data are
expressed in grams (g) and presented as meanSEM. This figure
is available in colour online at wileyonlinelibrary.com/journal/ptr.
Phytother. Res. (2012)
Figure 4. Plasma sFlt1 levels for CON, PRE and EK2. Plasma sFlt1
levels were determined by quantitative sandwich enzyme
immunoassay. The data are expressed in picograms per millilitre
(pg/mL) and presented as meanSEM, where (***) is p<0.001
for PRE versus CON and EK2. This figure is available in colour
online at wileyonlinelibrary.com/journal/ptr.
Figure 5. Plasma sEng levels for CON, PRE and EK2. Plasma sEng
levels were determined by quantitative sandwich enzyme immuno-
assay. The data are expressed in nanograms per millilitre (ng/mL)
and presented asmeanSEM,where (**) is p<0.01 for EK2 versus
PRE. This figure is available in colour online at wileyonlinelibrary.
com/journal/ptr.
S. V. RAMESAR ET AL.Plasma nitric oxide concentration
The plasma levels of NO in PRE (9.87 0.59 uM) and
EK2 (9.75 1.68 uM) were decreased compared with
CON (11.20 1.05 uM), however, this did not reach
statistical significance (p> 0.05; Fig. 6).DISCUSSION
Elevated arterial blood pressure is not uncommon
during pregnancy (Khalil and Granger, 2002; Sibai
et al., 2005; Thadhani et al., 2005). It has even been
documented in normal pregnancies of the Sprague–Figure 6. Plasma nitric oxide levels for CON, PRE and EK2. Plasma
nitric oxide levels were determined by ELIZA. The data are expressed
in micromoles (mM) and presented as meanSEM. This figure is
available in colour online at wileyonlinelibrary.com/journal/ptr.
Copyright © 2012 John Wiley & Sons, Ltd.Dawley rat (Olatunji-Bello et al., 2001), thus the
increase seen in all three groups was somewhat
expected. The PRE group, however, showed a 36.11%
increase in systolic blood pressure compared with the
CON group, which showed a 13.27% increase, and the
EK2 group, which showed a 20.26 % increase. It is
therefore interesting to note that although Kr2 did
not eliminate the L-NAME induced hypertension
completely, it certainly attenuated its effects.
A significant and exciting finding of this study was the
improved fetal mortality in the EK2 group when
compared with the PRE group. As the pregnancies
in both groups were compromised by administering
L-NAME in their drinking waters, the decreased
number of live pups seen in the PRE group was
expected. However, the co-administration of Kr2 in
the EK2 group significantly increased the number of live
pups. This indicates that the pyrano-isoflavone (Kr2)
has potential benefits in improving fetal mortality
during compromised pregnancies. The corresponding
fetal and placental weights were also greater in the
EK2 group compared with the PRE group and although
it did not reach statistical significance it illustrates that
the compound reduces intrauterine growth retardation
(IUGR) and improves placental perfusion because
these values compared closely with that of the CON
group.
These initial findings certainly warrant further investi-
gations into the possible underlying mechanisms by
which the bioactive compound improved these fetal
outcomes even though certain parameters did not reach
statistical significance.
Since VEGF and PlGF are central in the process of
vascular remodelling during pregnancy we screened
the blood plasma to identify possible changes relating
to these factors. The plasma levels of both factors
(VEGF and PlGF) did not vary amongst all three
groups, where all the groups exhibited very low levels.
Since vascular remodelling occurs early in the first
trimester and we collected blood samples close to term,
these results were expected. Future investigations
should aim at collecting blood samples at various inter-
vals of the gestation period for biochemical screening.
Recent studies draw a lot of attention to the role of
two antiangiogenic factors, i.e. sFlt1 and sEng in the
possible pathogenesis and exacerbation of pre-eclampsia
(Maynard et al., 2003, 2005; Thadhani et al., 2005; Sibai
et al., 2005; Venkatesha et al., 2006). Placental hypoxia,
as seen in pre-eclampsia, results in increased secretion
of sFlt-1 (Karumanchi and Bdolah, 2004). The latter is
thought to further decrease placental perfusion resulting
in a hypoxic placenta, this placental hypoxia stimulates a
further release of sFlt1 resulting in a worsening of the
condition (Karumanchi and Bdolah, 2004). Elevated
plasma sFlt-1 levels are thought to cause maternal
endothelial dysfunction, which could be responsible for
the elevated systolic blood pressure in the PRE group
(Bdolah et al., 2004).
Treatment with the bioactive compound, Kr2, resulted
in decreased plasma sFlt-1 concentration in the EK2
group thereby leading to a suppression of systolic blood
pressure in this group.We are of the view that administra-
tion of the bioactive compound in the EK2 group would
have improved placental blood flow, resulting in the
improved fetal outcomes mentioned above and improve-
ment in maternal systolic blood pressure.Phytother. Res. (2012)
KRAUSSIANONE-2 IMPROVES FETAL OUTCOMES IN A PRE-ECLAMPTIC RAT MODELFurthermore, administration of the bioactive com-
pound in the EK2 group also significantly decreased
plasma sEng levels. sEng has been shown to attenuate
the effects of TGF-b1 and TGF-b3 in rat renal microves-
sels by interfering with TGF-b receptor binding on
endothelial cells, resulting in decreased signalling
(Venkatesha et al., 2006). It is thought to act in ‘concert’
with sFlt1 to block the proangiogenic effects of VEGF
and TGF-b1 and disrupt endothelial integrity, thereby
causing considerable vascular damage (Venkatesha
et al., 2006). It is therefore promising to see that sEng
levels were also reduced by the bioactive compound.
We thus aimed to determine a possible mechanism of
action for Kr2. As it has been shown to improve erectile
dysfunction (Drewes et al., 2002, 2003; Ojewole et al.,
2006) we aimed to compare its mechanism of action to
a well-known drug, Viagra™. Sildenafil citrate as men-
tioned earlier, is a type-5 PDE inhibitor, potentiating
the vasodilatory effects of NO. We therefore, measured
the plasma levels of NO to determine whether Kr2
improves its availability. Unfortunately there was no
significant difference in the plasma NO levels amongst
all three groups. This finding indicates that Kr2 works
through some alternative pathway to cause the uterine
vasodilation. It is consistent with the findings of Drewes
et al., (2002, 2003), who also suggest that the compound
has a different mechanism of action when compared
with Viagra™ in producing vasorelaxation.
Valdes et al. (2009) propose that there are five
vasodilatory factors/systems that have a functional role
in maintaining normotension during pregnancy. These
five are prostacyclin, nitric oxide, kallikrein, angiotensin-Copyright © 2012 John Wiley & Sons, Ltd.(1–7) and VEGF. The expression of these vasodilators,
either in the different trophoblastic subtypes or in the
fetal endothelium in humans, rats and guinea-pigs,
suggests that they oppose the effects of certain vasocon-
strictor systems in vivo or participate directly in vascular
remodelling, thus maintaining the uteroplacental circula-
tion (Valdes et al., 2009). Our experiment rules out the
possibility of increased nitric oxide or VEGF as a mech-
anism by which Kr2 improves uteroplacental blood flow
because neither of the factors were increased by Kr2
treatment. Future research in this field should investigate
prostacyclin, kallikrein and angiotensin-(1–7) as a possi-
bility of improving maternal blood pressure regulation
and uteroplacental blood flow.
The findings of this experiment, however, strengthen
our assertion that improved uteroplacental blood flow
will reduce the symptoms of pre-eclampsia irrespective
of the predisposing factors for the disease.Acknowledgements
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Pre-eclampsia is a complex disease that affects both mother and their developing fetus. 
Due to the multifactorial nature of the disease and its undeciphered etiology, we 
explore the possibility of improving intrinsic vasodilatory mechanisms as a method of 
treatment. Reduced utero-placental blood flow seems to be central in the manifestation 
of this disease leading to the secretions of various factors that maintain and/or worsen 
the condition. We and various other researchers have showed that improved placental 
perfusion shows promise in alleviating many symptoms of the disease. This serves as 
an excellent option at reducing both perinatal and maternal morbidity and mortality 
irrespective of the predisposing factors for the disease.   
 





Pre-eclampsia, is one of the most widely investigated conditions relating to human 
reproduction. To date no firm cure has been found, and a clear, well-defined 
mechanism has not been ascribed to the pathogenesis of the disorder. Some researchers 
seem to focus on single pathways in isolation of others.  The disease rather represents a 
multitude of possible underlying pathologies involving genetics, immune 
dysregulation, vascular maladaptation and sociobiological factors; complicating 
clinical management. However, a central theme is the presence of reduced placental 
perfusion resulting in a hypoxic and/or ischaemic placenta, delivery of which results in 
a resolution of clinical symptoms. It is within this context that we examine how an 
intervention such as increasing placental perfusion may represent a promising 
treatment strategy for reducing maternal and neonatal mortality and morbidity related 
to the pre–eclampsia/ eclampsia syndrome in low resource environments.    
 
 




Pre-eclampsia is a specific disorder of human pregnancy, which is commonly 
characterised by hypertension and proteinuria after 20 weeks of gestation. It should 
however be recognised as a multi system disorder in which one organ system may also 
be predominantly affected. Thus, the disorder may present as isolated 
thrombocytopenia or intrauterine growth restriction (IUGR). [1,2,3].  Steegers et al. 
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(2010)  also makes the point that pre-eclampsia, sometimes progresses into a multi-




The worldwide incidence of pre-eclampsia is estimated to be approximately 8,370,000 
cases per annum [3]. Each year, 814,000 neonatal deaths and 1.02 million stillbirths 
result from intrapartum-related causes, such as intrauterine hypoxia with pre-eclampsia 
being one of the major risk factors. Thus the disease is said to be the leading cause of 
both maternal and fetal morbidity and mortality, especially in low and middle income 
countries (LMIC)[5,6,7,3]. Locally, 84% of the 622 deaths linked to hypertensive 
disorders in pregnancy between 2005 and 2007 were due to the pre-eclampsia/ 
eclampsia syndrome [8]. Furthermore, the incidence of hypertension in pregnancy, in a 
population based study in this Province was 12.5% in 2004 [9]. In sub-Saharan Africa, 
recent health services assessments found that only 15% of all hospitals where equipped 
to provide basic neonatal resuscitation, [10] and with increased daily admissions of 
pre-eclamptic patients this is  an added burden to healthcare in LMIC countries. 
Maternal deaths from hypertensive disorders in pregnancy are also a common in high 
income countries [7], and is the foremost cause for the admission of pregnant women 




Because of the multifactorial pathogenesis of the different pre-eclampsia phenotypes, 
classification has been somewhat difficult [11].  Despite this, Wagner (2004) has 
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attempted to classify the different hypertensive disorders of pregnancy into four main 
types; chronic hypertension gestational hypertension, pre-eclampsia superimposed on 
chronic hypertension and pre-eclampsia (Figure 1) [12].  Basically, chronic 
hypertension refers to the presence of hypertension before 20 weeks of gestation in the 
absence of, or stable proteinuria.  Gestational hypertension refers to hypertension after 
20 weeks of gestation without proteinuria.  A patient with hypertension before 20 
weeks gestation, and  a further increase in blood pressure; along with de-novo 
proteinuria or a sudden increase in existing proteinuria, may be diagnosed as having 










3. Etiology and Pathogenesis of preeclampsia 
The etiology and pathophysiology of pre-eclampsia is still not clearly understood, 
however many accept a two-stage model of the disease.  It is known that the 
pathogenic process begins much earlier than the symptoms; perhaps at the onset of 
trophoblastic invasion and remodelling of the spiral arteries during the first trimester of 
pregnancy [13]. Therefore, the first stage is vascular maladaptation in the placental 
bed, due to the failure of the uterine spiral arteries to undergo complete remodelling 
into wide bore channels;  an important vascular modification in normal pregnancies 
[14,15,1,16]This maladaptation is associated with a marked reduction in blood flow to 
the placenta. The second stage, the maternal stage, is one in which the reduced 
placental perfusion results in  release of a variety of substances; including trophoblastic 
debris; necrotic tissue; and an  excess secretion of factors, which affect virtually every 
major organ system through  endothelial dysfunction and systemic vasospasm.  These 
events are depicted sequentially in figure 2. 
 
Figure 2: The onion model for the etiology of pre-eclampsia. 
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4. Reduced uterine and placental perfusion  
A key event in the etiopathology of the disease is considered to be the inability of the 
extravillous trophoblast (EVT) to change their phenotype to a more invasive type 
which is needed for vascular remodelling.  The arteries fail to remodel into wide bore 
“compliance” vessels, offering little resistance but they rather act as resistance vessels 
resulting in a marked reduction in blood flow to the placenta [1,2,15].  What exactly 
causes these EVT to display this aberrant behaviour is not clear. The resulting hypoxic 
placenta secretes excess soluble fms-like tyrosine kinase-1 (sFlt1) into maternal 
circulation [17]. This excess sFlt1 has been shown contribute to hypertension, 
proteinuria, endothelial dysfunction and IUGR, which are classic phenotypes of this 
disease[18] .  The increased circulating level of sFlt-1 is thought to play a role in the 
development of hypertension by opposing the physiological effects of NO-dependant 
vasodilation [19].  Others have suggested that elevated circulating sFlt-1 may also 
result in proteinuria by down regulating renal nephrin[20].  Since placental and fetal 
weights are strongly correlated with uteroplacental blood flow  it certainly accounts for 
the IUGR[21].  
 
5. Substances that can alter uterine vascular dilation 
Valdes et al. (2009) proposed that there are five vasodilatory factors/systems that have 
a functional role in maintaining normotension during pregnancy. These five are 
prostacyclin, nitric oxide, kallikrein, angiotensin-(1–7) and VEGF-A[22]. The 
expression of these vasodilators either in the different trophoblastic subtypes, or in the 
fetal endothelium in humans, rats, guinea-pigs and sheep, suggests that they oppose 




The role of prostanoids in pregnancy was investigated as early as the 1970’s, with the 
two main protagonists of the system being prostacyclin (PGI2) and thromboxane A2 
(TXA2)[23,24,25]. Both vasoactive factors are synthesized from prostaglandin (PGH2), 
which is ultimately metabolised from arachidonic acid under the influence of the 
enzymes, constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-
2). Prostacyclin synthase and thromboxane synthase are the two enzymes responsible 
for the synthesis of PGI2 and TXA2 respectively.  The distribution of these enzymes 
therefore makes this cascade very cell specific. 
 
Prostacyclin is a major vasodilator, synthesized from the endothelium, [26] whereas 
TXA2 is a potent vasoconstrictor and procoagulant derived from platelets. PGI2 thus 
mediates its effects directly on the smooth muscle of blood vessels or by opposing the 
effects of TXA2.  In normal pregnancies the excretion of urinary metabolites of PGI2
demonstrates a steady and marked rise with almost a fivefold increase near term, 
however the urinary excretion of thromboxane metabolites remains unchanged, 
indicating a net vasodilatory effect.  In preeclampsia, decreased urinary excretion of 
the PGI2 metabolites are observed from as early as 13 weeks of pregnancy[27] and 
elevated TXA2 levels are seen after 21 weeks, ultimately favouring the vasoconstrictor 
effect.  This decreased PGI2 levels and increased TXA2 levels have been attributed to 
increased lipid peroxidation and decreased scavengers in preeclamptic patients [28]. 
These findings   initiated a large scale clinical trial using low dose aspirin; a 
cyclooxygenase inhibitor, which only showed a modest reduction in the incidence of 
the disease [29]. 
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5.2. Nitric oxide 
Nitric oxide is produced by the deamination of L-arginine into citrulline and NO in the 
presence of the enzyme nitric oxide synthase (NOS) [30]. There are 3 isoforms of this 
enzyme, i.e. endothelial NOS (eNOS), neuronal NOS (nNOS) and inducible NOS 
(iNOS).  In the case of vasculature, eNOS is the dominant isoform [30,31,32].  Nitric 
oxide exerts its vasodilatory effects through the action of its second messenger, cyclic 
guanidine monophosphate (cGMP), which is produced as a result of NO interaction 
with an iron molecule in the enzyme guanylyl cyclase to ultimately phosphorylate 
guanidine triphosphate (GTP) into cGMP [30].  
The role of NO in pregnancy has been widely reported, however in  this review we 
allude to a few pertinent studies.  Plasma and urinary levels of nitrate, and urinary 
levels of cGMP are shown to be increased throughout pregnancy [33,34] .Exogenous 
blockade of NO synthesis in animal models has been shown to mimic the effects of 
pre-eclampsia [35,36]. In addition, elevated levels of the endogenous NOS inhibitor, 
dimethylarginine (ADMA), in the second trimester of pregnancy, is associated with 
endothelial dysfunction, impaired uterine artery blood flow and the subsequent 
development of preeclampsia [37]. 
Further evidence for the importance of NO in pregnancy was demonstrated in a few 
clinical trials where hypertensive pregnant patients were supplemented with L-arginine 
(NO substrate) and exhibited an improvement in both systemic and placental perfusion, 
coupled with an improvement in blood pressure[38,39,41]. These findings certainly 
warrant further investigations with L-arginine supplementation. It is within this context 
that we chose to study sildenafil citrate as a NO donor, which yielded beneficial 
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outcomes to pregnancies complicated by a reduction in uterine perfusion pressure 
(RUPP)[42].  
5.3. Kallikrein-kinin system 
The kallikrein-kinin system is best described as an endogenous cascade whereby the 
two kinins, kallidin and bradykinin, are cleaved from either low or high molecular 
weight kininogens by two serine proteases, namely tissue and plasma kallikrein [22]. 
Both kinins elicit their effect by binding to one of two receptors, kinin type 1 receptor 
(B1R) or kinin type 2 receptor (B2R).  Kinin type 1 receptor activation promotes 
angiogenesis, mitogenesis and induces pain, whereas B2R activation is associated with 
increased vascular permeability, decreased platelet aggregation and vasodilation.  The 
latter effects are either directly mediated by B2R activation or indirectly by the 
synthesis of NO and/or PGI2 [43]. Increased urinary kallikrein excretion is associated 
with normal pregnancies and reaches its maximum by 8-12 weeks of gestation [44]. 
This rise in urinary kallikrein excretion is not observed in hypertensive pregnancies 
[45,46] and even lower levels are observed in patients destined for preeclampsia [47] 
suggesting that the kallikrein-kinin system plays a functional role in maintaining 
placental perfusion. 
5.4. Vasodilator components of the renin-angiotensin system 
The renin-angiotensin system (RAS) is an established vasoconstrictor system; however 
recent reports also allude to a vasodilator arm of this cascade.  The latter effects are 
mediated through angiotensin (1-7) [ang 1-7] which act on the Mas receptor to cause 
vasodilation, angiogenesis, collagen production, thrombosis and inhibition of vascular 
smooth muscle growth.  Ang 1-7 is linked to the RAS by angiotensin converting 
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enzyme 2 (ACE-2), and may be produced by any one of three biochemical pathways. 
The first mechanism of ang 1-7 production is by the cleavage of one amino acid from 
angiotensin II [ang II] by ACE-2, propyl endopeptidase (PEP) or carboxypeptidase 
(CPB).  Secondly, ang 1-7 may be produced by the cleavage of 3 amino acids from 
angiotensin I [ang I] by neutral endopeptidase (NEP) and thirdly, ang 1-7 may be 
produced by a two-step reaction, where ang I is converted to angiotensin 1-9 [ang 1-9] 
by ACE-2, followed by the cleavage of 2 amino acids by angiotensin converting 
enzyme (ACE) and NEP.   
Urinary and plasma levels of ang 1-7 have been shown to increase throughout normal 
pregnancies and are reduced in pre-eclampsia, suggesting that this vasodilator plays an 
important role in the vascular adaptations to pregnancy [48,49,50]. Further evidence 
supporting this notion was seen in a RUPP model that mimics preeclampsia, where it 
was shown that ang 1-7 and ACE-2 mRNA expression was decreased in the placenta 
[51,52,53]. This suggests that RUPP associated with pre-eclampsia inhibits the 
vasodilator arm of RAS possibly through factors such as sFlt-1, TNF-α or angiotensin 
type 1 receptor auto-antibody that are secreted as a consequence of placental hypoxia 
and decreased placental blood flow [51,52,53].The effects of ang II, mediated by the 
AT1 receptor, is well documented with the most common being vasoconstriction, cell 
proliferation, fibrosis and angiogenesis. In contrast  is the binding of ang II to the AT2 
receptor resulting in  opposite effects i.e. vasodilation, antiproliferative, antifibrotic 
and antiangiogenic,  mediated by eNOS and kinins [54,55,56]. The role of ang II as a 
vasodilator in pregnancy was highlighted in a study that showed that ang II was absent 
in the uterine arteries of non-pregnant sheep as compared to pregnant ewes that 
underwent normal pregnancy [57,58]. 
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 5.5. VEGF-A as a vasodilator:  
Vascular endothelial growth factor -type A (VEGF-A) is one of the 4 isoforms of 
vascular endothelial growth factor (VEGF) and is known to promote angiogenesis by 
inducing  vascular permeability, cell migration and protease production by endothelial 
cells[59,60]. This role in vascular remodeling during placentation is shared by 
placental growth factor (PlGF) and angiopoietins 1 and 2 [61].  
VEGF can also cause vasodilation by binding to tyrosine kinase-1 type fms receptors 
(VEGFR-1 [Flt-1]), which are modulated by VEGFR-2 (Flk-1/kinase domain [KDR]) 
receptors [60,62]. This receptor binding activates eNOS to produce NO [63] as well as 
PGI2 synthesis from PGH2 [64]. In a study conducted by Brownbill and colleagues 
(2007), where VEGF was perfused in human placentas, a strong vasodilatory effect 
was observed in the placental vasculature, which was later shown to be mediated by 
NO [65].  In another study conducted by Brockelsby and colleagues (2000), VEGF was 
shown to increase PGI2 synthesis in bovine endothelial cells thereby causing 
vasodilation [66]. 
As mentioned earlier, the hypoxic placenta which is characteristic of pre-eclampsia has 
been shown to secrete excessive amounts of sFlt1 into maternal circulation [17] This is 
a soluble form of the Flt-1 receptor that is generated by alternative splicing [67]. Free 
VEGF therefore binds to the vast amounts of circulating sFlt1 thereby reducing its role 
in either vascular remodeling and/or fetoplacental vasodilation which are both crucial 




6. Current management strategies and proposed interventions 
To date there is no known treatment for preeclampsia.  The only known cure is the 
delivery of both the fetus and the placenta. However, early delivery may place the fetus 
at risk of prematurity and subsequent perinatal morbidity and mortality. Thus prior to 
fetal viability treatment is aimed at lowering high blood pressure, thus reducing 
maternal complications while awaiting fetal maturity. Commonly used anti-
hypertensive agents cause systemic vasodilation and can only slightly improve blood 
pressure control, but have no significant clinical effects on improving renal function 
and increasing placental blood flow. It is the decreased blood flow to the placenta that 
ultimately leads to IUGR and a multi system endothelial dysfunction.  
 
Since the etiology and pathogenesis of the pre-eclampsia remains elusive and given the 
multi-factorial complexity of the disease, investigators should therefore focus on 
treatments that can increase utero-placental blood flow by manipulating any of the five 
proposed mechanisms for uterine vascular dilation.  This in essence should cause 
improved placental perfusion and hence decrease placental hypoxia and subsequently 
decrease the secretion of the anti-angiogenic factors that aggravate the disease.  This 
would ideally offer a treatment to pre-eclampsia irrespective of the predisposing 
factors for the disease. 
 6.1. Sildenafil citrate and the Nitric Oxide Pathway  
As mentioned earlier, nitric oxide (NO) is a locally active vasodilator that relaxes 
vascular smooth muscle directly through a cGMP-mediated pathway, and indirectly by 
inhibiting the production of vasoconstrictors including endothelin – 1 (ET1) [30, 68, 
69,]. In recent years, animal research has demonstrated that NO leads to relaxation of 
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vascular smooth muscles and is a powerful modulator of uterine blood flow [70,71].  
Furthermore, the findings of Gokina et al (2003) suggest that any decrease in NO 
production would result in an increase in uterine artery myogenic tone and decreased 
placental blood flow [72], possibly resulting in placental hypoperfusion, with 
subsequent development of hypertension or preeclampsia. 
 
The mechanism of action for sildenafil citrate is based on this role of nitric oxide (NO) 
on vascular smooth muscle relaxation [73].  Sildenafil citrate (ViagraTM) is a specific 
type-5 phosphodiesterase (PDE) inhibitor. It acts as a competitive binding agent for 
this type-5 phosphodiesterase and therefore favours cGMP to cause vasodilation of the 
penile artery and relaxation of the corpora cavernosa to ultimately cause an erection 
[73].   
 
With the discovery of the same family of specific type-5 phosphodiesterase iso-
enzymes in the uterus and uterine vasculature [74,75] sildenafil citrate certainly 
warranted investigations into its vasodilatory effect in the female reproductive system. 
Researchers have also shown sildenafil citrate to improve uterine artery blood flow and 
endometrial development in women undergoing i  vitro fertilization [76], as well as 
having beneficial effects on fetal and vascular parameters in hypertensive pregnant rats 
[77]. Sildenafil citrate was also shown to enhance vasodilation and improve the 
endothelial function of myometrial vessels in pregnancies complicated by intra-uterine 
growth retardation (IUGR) [78]. In a rat pre-eclamptic model, sildenafil citrate 
increased cGMP content in thoracic aortic muscle rings and straightened the relaxation 
and contraction responses, however not to control levels [79].  Studies conducted in 
our laboratories have shown sildenafil citrate to improve fetal outcomes, decrease 
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proteinuria and reduce blood pressure amplification in rats with pre-eclampsia-like 
manifestations [80].  We further demonstrated that sildenafil citrate decreased sFlt1 
and sEng levels and showed a slight improvement in NO levels in the same model 
[42]. 
 
As mentioned previously, exogenous gene transfer of sFlt-1 in pregnant rats displayed 
various phenotypes of pre-eclampsia including hypertension, proteinuria and 
glomerular endotheliosis [18,17] and the co-administration of sEng in the same animal 
caused haemolysis and thrombocytopenia which are also notable phenotypes of the 
disease.  Since both of these anti-angiogenic factors were decreased by sildenafil 
citrate, it serves as a promising treatment for pre-eclampsia and certainly warrants 
human trials.  
 
 
6.2. Eriosema kraussianum N. E. Br. (Fabaceae) 
Traditional herbal remedies form an integral part of African culture. Given the success 
of sildenafil citrate on pre-eclampsia-like manifestations in rats, and the expense of 
ViagraTM, we chose to investigate the role of a plant extractive that is commonly used 
by South African traditional healers for erectile dysfunction (ED) [81]. This plant is 
classified under the genus, Eriosema (isiZulu indigenous umbrella name of 
“uBangalala”). The roots of Eriosema kraussianum are used by Zulu traditional 
healers to treat ED as follows; hot milk infusions of the plant’s roots or pounded, 
boiled root decoctions are taken in small doses twice a day for impotence [81,82,83]. 
Two bioactive pyrano-isoflavones [Kraussianone-1 (Kr1) and Kraussianone-2 (Kr2)] 
were isolated from the roots of Eriosema kraussianum N. E. Br. (Fabaceae) [84,85]. 
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Both bioactive compounds demonstrated beneficial effects in the management of ED 
[84,85] and further exhibited hypoglycaemic effects and vasodilatory properties in a rat 
model [86].  To this end, we investigated the effect of Kr2 on pre-eclampsia-like 
manifestations in a rat model [87].  We demonstrated that Kr2 administration improved 
pup survival and showed a trend toward increasing birth and placental weights. 
Furthermore, Kr2 administration also reduced blood pressure amplification and 
decreased the plasma concentrations of the two anti-angiogenic factors, sFlt-1 and 
sEng.  We did not see an improvement in NO levels, suggesting that the plant 
extractive exerts a vasodilatory effect by some other mechanism. However we 
speculate that Kr2, by improving uterine artery blood flow, results in the improved 
fetal outcomes.  
 
7. Conclusion 
Several studies show that improved uteroplacental blood flow will reduce the 
symptoms of preeclampsia, irrespective of the etiopathology of the disease.  Research 
conducted in our laboratories reinforced this concept using two different compounds 
that cause specific vasodilation by different mechanisms. Since both compounds 
improved fetal outcomes including birth and placental weights, it is plausible that there 
was improved placental perfusion as a result of selective vasodilation which has helped 
to alleviate the symptoms associated with pre-eclampsia.  The promising results seen in 
our animal model warrants further studies whereby sildenafil citrate or kraussianone-2 
should be administered at different gestation intervals; while monitoring the circulating 
anti-angiogenic levels.   
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Treatment using sildenafil citrate, should specifically target mothers that exhibit 
increasing levels of sFlt1 and sEng even before 20 weeks of gestation; with continuous 
monitoring of blood pressure, urinary protein excretion and platelet count. Given the 
complex multifactorial nature of this disease and the elusive nature of its eitiology, our 
recommendation represents a viable option to decrease perinatal and maternal 
morbidity and mortality from pre-eclampsia. 
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Several studies show that improved utero-placental blood flow will reduce the symptoms of 
preeclampsia, irrespective of the etiopathology of the disease.  Research conducted in our 
laboratories reinforced this concept using two different compounds that cause specific 
vasodilation by different mechanisms. Both compounds improved fetal outcomes including 
birth and placental weights, and most importantly increased pup survival.  The compounds 
also reduced blood pressure amplification and decreased urinary protein excretion, thereby 
eliminating the most notable phenotypes of this disease. Upon further investigation it was 
also noted that the compound decreased SFlt1 and sEng levels. It is plausible that there was 
an improvement in placental perfusion as a direct result of selective uterine vasodilation 
which has subsequently helped to alleviate the symptoms associated with pre-eclampsia. 
Given the complex multifactorial nature of this disease and the elusive nature of its eitiology, 
our recommendation represents a viable option to decrease perinatal and maternal morbidity 
























The promising results seen in our animal model warrants further studies whereby sildenafil 
citrate or kraussianone-2 should be administered at different gestation intervals; while 
monitoring the circulating anti-angiogenic levels.   
 
Certain variables measured only demonstrated a trend of increase or decrease but did not 
reach statistical significance, therefore research teams should aim to undertake larger trails 
using a greater sample population to achieve statistical significance. 
 
Clinical trials using sildenafil citrate, should specifically target mothers that exhibit 
increasing levels of sFlt1 and sEng even before 20 weeks of gestation; with continuous 
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